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 Estrogen receptor positive breast cancer remains 
the commonest form of metastatic incurable disease. 
Although estrogenic signalling in breast cancer is one of 
the most critical oncogenic pathways known, there are 
no specific therapies designed to overcome endocrine 
resistance. This is in contrast to the situation in less 
common types of breast cancer including triple negative 
disease (PARP inhibitors) and HER2 positive relapsed 
tumours (T-DM1 and neratinib, amongst others). 
As kinases are some of the most common drug targets 
[1], we sought to identify previously uncharacterized 
molecules that regulate the estrogen receptor-α (ERα) 
[2,3]. To start with, we performed a ‘high risk’ screen 
using expression of the estrogen responsive gene pS2 as 
a read-out, as opposed to standard sets of results such as 
measures of cell proliferation. Known kinases including 
MAPK3 and Akt that modulate activity of ERα via 
phosphorylation were used as controls. 
Changes in DNA sequences have been proposed 
to play distinctive roles in adaptive evolution. While 
presumably all proteins must have been positively 
selected for their biochemical functions at some time in 
the past, only a very few show protein-coding sequence 
evidence of such adaptive evolution; we thought it 
notable that LMTK3 fell into this category. An excess of 
nonsynonymous (coding) over synonymous (non-coding, 
silent) codon mutations was used to identify sites of 
positive selection and clarified that only LMTK3 amongst 
all the molecules we studied had adaptively evolved. We 
therefore decided to focus our attention on LMTK3; 
in doing so, we attempted to explain in part the unique 
susceptibility of humans to ERα positive breast cancers.
Interestingly, reproductive proteins are among the 
fastest evolving in the genome and several models have 
been proposed to explain this including sexual conflict and 
sexual selection [4]. It is therefore of enormous interest 
that an ERα modulating kinase was the only protein we 
observed to be positively selected in our screen. It is 
also significant that the LMTK1 and LMTK2 isoforms 
have not been positively selected between human and 
chimpanzees; they are well-conserved. We demonstrated 
that positive selection occurred across the LMTK3 gene 
except for the catalytic core domain, presumably altering 
substrate binding characteristics of human vs. chimpanzee 
LMTK3. While the selective pressure that drove this 
adaptive event is at present unclear, an evolutionary trade-
off may have led to increased human susceptibility to this 
disease.
Having shown that methylation was unlikely to play 
a role here but the presence of certain single nucleotide 
polymorphisms (SNPs) may be relevant, we compared 
human and non-human primate (NHP) SNPs. Most 
humans we examined had the ‘protective’ TT allele, 
while the less-susceptible NHPs lack the protective 
TT allele, perhaps as a result of selective pressure to 
counter possible deleterious effects of sequence changes 
to human LMTK3. In effect we are postulating two 
selective pressures/events: one on the protein sequence/
structure and another on the frequency of the TT SNP 
in the LMTK3 intron. The second event was thus likely 
compensatory for changes that occurred in the first event, 
which altered the protein itself. We acknowledge that it 
is of course possible that the positively selected amino 
acid replacements in human LMTK3 are not responsible 
for the documented human susceptibility to breast cancer; 
it is still the case however, that the TT allele our data 
suggests to be protective in humans is present at far lower 
frequencies in the less-susceptible NHPs, suggesting that 
the difference in allelic frequency compensates at least 
in part for greater human susceptibility to breast cancer. 
The allelic differences in LMTK3 intron are we believe 
likely to impact gene expression/regulation of LMTK3 or 
nearby genes.
In aggregate, these data demonstrate the use of 
evolutionary analyses to refine results and select proteins 
for further study. Such data will also assist in discovery 
of relevant protein-protein interacting regions. We think 
our subsequent mechanistic and clinical outcomes data 
attest to this, though there is much to be learnt to clarify 
mechanisms of endocrine resistance. The identity of a 
new kinase with a role in this process may be fundamental 
to future work in this area.
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